Genscript Biotech Company Top Insiders

GNNSF Stock  USD 1.25  0.01  0.79%   
Genscript Biotech employs about 5.6 K people. The company is managed by 10 executives with a total tenure of roughly 43 years, averaging almost 4.0 years of service per executive, having 557.3 employees per reported executive. Examination of Genscript Biotech's management performance can provide insight into the company performance.
Li Zhu  President
Vice President - Strategy
Jiange Meng  President
Vice President - Finance, Executive Director
  
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Genscript Biotech. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state.

Genscript Biotech Management Team Effectiveness

The company has return on total asset (ROA) of (0.1165) % which means that it has lost $0.1165 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.5574) %, meaning that it generated substantial loss on money invested by shareholders. Genscript Biotech's management efficiency ratios could be used to measure how well Genscript Biotech manages its routine affairs as well as how well it operates its assets and liabilities.

Genscript Biotech Workforce Comparison

Genscript Biotech is one of the top stocks in number of employees category among its peers. The total workforce of Biotechnology industry is currently estimated at about 31,183. Genscript Biotech retains roughly 5,573 in number of employees claiming about 18% of stocks in Biotechnology industry.
The company has Profit Margin (PM) of (0.66) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (0.64) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $0.64.

Genscript Biotech Benchmark Summation

Operator
The output start index for this execution was zero with a total number of output elements of sixty-one. Genscript Biotech Price Series Summation is a cross summation of Genscript Biotech price series and its benchmark/peer.

Genscript Biotech Notable Stakeholders

A Genscript Biotech stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Genscript Biotech often face trade-offs trying to please all of them. Genscript Biotech's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Genscript Biotech's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Li ZhuVice President - StrategyProfile
Jiange MengVice President - Finance, Executive DirectorProfile
Shiniu WeiChief OfficerProfile
Brian MinCEO BusProfile
Zhenyu LiuChief OfficerProfile
Weihui ShaoChief OfficerProfile
Chifa ZhangDepartment head - industry synthetic biology product segmentProfile
ACIS ACSCompany SecProfile
Ye MSPres CoFounderProfile
ChuanChu ChouDepartment head - Preclinical Drug Development Service Business SegmentProfile

About Genscript Biotech Management Performance

The success or failure of an entity such as Genscript Biotech often depends on how effective the management is. Genscript Biotech management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Genscript management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Genscript management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Genscript Biotech Corporation, an investment holding company, engages in the manufacture and sale of life science research products and services in North America, Europe, the Peoples Republic of China, Japan, the other Asia Pacific regions, and internationally. Genscript Biotech Corporation was founded in 2002 and is headquartered in Nanjing, the Peoples Republic of China. Genscript Biotech operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 5573 people.

Genscript Biotech Workforce Analysis

Traditionally, organizations such as Genscript Biotech use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Genscript Biotech within its industry.

Genscript Biotech Manpower Efficiency

Return on Genscript Biotech Manpower

Revenue Per Employee91.6K
Revenue Per Executive51.1M
Net Loss Per Employee62.4K
Net Loss Per Executive34.8M

Complementary Tools for Genscript Pink Sheet analysis

When running Genscript Biotech's price analysis, check to measure Genscript Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Genscript Biotech is operating at the current time. Most of Genscript Biotech's value examination focuses on studying past and present price action to predict the probability of Genscript Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Genscript Biotech's price. Additionally, you may evaluate how the addition of Genscript Biotech to your portfolios can decrease your overall portfolio volatility.
Watchlist Optimization
Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm
Pair Correlation
Compare performance and examine fundamental relationship between any two equity instruments
Equity Analysis
Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities
Stock Screener
Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook.
Portfolio Volatility
Check portfolio volatility and analyze historical return density to properly model market risk
Money Managers
Screen money managers from public funds and ETFs managed around the world
My Watchlist Analysis
Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like
AI Portfolio Architect
Use AI to generate optimal portfolios and find profitable investment opportunities
Equity Valuation
Check real value of public entities based on technical and fundamental data